Phase 1CompletedINTERVENTIONAL
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
ClinicalTrials.gov · NCT05377333 · Registry updated: 2024-01-11
- Condition / research focus
- Diabetes Mellitus, Type 2
- Sponsor
- Eli Lilly and Company
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2022-06-02. Completion: 2023-11-22 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- LY3457263 (drug)
- Placebo (drug)
- Dulaglutide (drug) — also listed as: LY2189265
Where the study takes place — 5 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Pinnacle Research Group, LLC
Anniston, Alabama, United States
Site recruitment: Not reported - CenExel ACT
Anaheim, California, United States
Site recruitment: Not reported - Qps-Mra, Llc
South Miami, Florida, United States
Site recruitment: Not reported - Atlanta Center of Medical Research
Atlanta, Georgia, United States
Site recruitment: Not reported - CenExel-HRI
Berlin, New Jersey, United States
Site recruitment: Not reported